Review



tumors  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Novus Biologicals tumors
    Tumors, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray/Human+Prostate+Tissue+MicroArray+(Cancer)/pmc04358924-88-14-18
    Average 93 stars, based on 24 article reviews
    tumors - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
    Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169). TMA cohort 2. A previously published 96 case TMA comprising duplicate cores of normal prostate tissue and prostate adenocarcinoma of different Gleason grades was purchased from

    Microarray:

    Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
    Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169). TMA cohort 2. A previously published 96 case TMA comprising duplicate cores of normal prostate tissue and prostate adenocarcinoma of different Gleason grades was purchased from

    Immunohistochemistry:

    Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
    Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169). TMA cohort 2. A previously published 96 case TMA comprising duplicate cores of normal prostate tissue and prostate adenocarcinoma of different Gleason grades was purchased from

    Immunofluorescence:

    Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
    Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169). TMA cohort 2. A previously published 96 case TMA comprising duplicate cores of normal prostate tissue and prostate adenocarcinoma of different Gleason grades was purchased from

    Imaging:

    Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
    Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169). TMA cohort 2. A previously published 96 case TMA comprising duplicate cores of normal prostate tissue and prostate adenocarcinoma of different Gleason grades was purchased from

    Staining:

    Article Title: Targeting Siglec-engaging immunosuppressive sialoglycans to suppress prostate cancer bone metastasis.
    Article Snippet: static prostate tumours and indicates the Siglec-sialoglycan axis can be clinically targeted to impede prostate cancer progression. TMA cohort 1. A 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169). TMA cohort 2. A previously published 96 case TMA comprising duplicate cores of normal prostate tissue and prostate adenocarcinoma of different Gleason grades was purchased from



    Similar Products

    fda999u fda999w  (Novus Biologicals)
    90
    Novus Biologicals fda999u fda999w
    Fda999u Fda999w, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray/Human+Prostate+Tissue+MicroArray+(Cancer)/pmc12767472-518-6-13
    Average 90 stars, based on 1 article reviews
    fda999u fda999w - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    nbp2  (Novus Biologicals)
    90
    Novus Biologicals nbp2
    Nbp2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray/Human+Prostate+Tissue+MicroArray+(Cancer)/pmc12767472-97-7-4
    Average 90 stars, based on 1 article reviews
    nbp2 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    case human prostate cancer tma  (Novus Biologicals)
    90
    Novus Biologicals case human prostate cancer tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Case Human Prostate Cancer Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray/Human+Prostate+Tissue+MicroArray+(Cancer)/bio_rxiv__2025__11__12__687981-134-5-13
    Average 90 stars, based on 1 article reviews
    case human prostate cancer tma - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    prostate cancer microarray  (Novus Biologicals)
    90
    Novus Biologicals prostate cancer microarray
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Prostate Cancer Microarray, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray/Human+Prostate+Tissue+MicroArray+(Cancer)/pm41005308-793-47-52
    Average 90 stars, based on 1 article reviews
    prostate cancer microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    human prostate cancer tissue microarray  (Servicebio Inc)
    86
    Servicebio Inc human prostate cancer tissue microarray
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Cancer Tissue Microarray, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray/microarray+tissue/pmc12434036-92-1-13
    Average 86 stars, based on 1 article reviews
    human prostate cancer tissue microarray - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    human prostate tissue microarrays (tmas) pr8011c  (US BIOLAB CORPORATION INC)
    90
    US BIOLAB CORPORATION INC human prostate tissue microarrays (tmas) pr8011c
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Tissue Microarrays (Tmas) Pr8011c, supplied by US BIOLAB CORPORATION INC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray/human+prostate+tissue+microarrays++tmas++pr8011c/pmc11952371-48-0-8
    Average 90 stars, based on 1 article reviews
    human prostate tissue microarrays (tmas) pr8011c - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    human prostate tissue microarrays containing normal prostate, normal adjacent, and pca tissue  (TissueArray.com LLC)
    90
    TissueArray.com LLC human prostate tissue microarrays containing normal prostate, normal adjacent, and pca tissue
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Tissue Microarrays Containing Normal Prostate, Normal Adjacent, And Pca Tissue, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray/human+prostate+tissue+microarrays+containing+normal+prostate++normal+adjacent++and+pca+tissue/pm39885202-383-10-15
    Average 90 stars, based on 1 article reviews
    human prostate tissue microarrays containing normal prostate, normal adjacent, and pca tissue - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    human prostate tissue microarray slides  (Biomax Inc)
    90
    Biomax Inc human prostate tissue microarray slides
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Tissue Microarray Slides, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+prostate+tissue+microarray/human+prostate+tissue+microarray+slides/pm37491794-82-0-8
    Average 90 stars, based on 1 article reviews
    human prostate tissue microarray slides - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

    Journal: bioRxiv

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

    doi: 10.1101/2025.11.12.687981

    Figure Lengend Snippet: ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Techniques: Immunohistochemistry, Staining

    ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

    Journal: bioRxiv

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

    doi: 10.1101/2025.11.12.687981

    Figure Lengend Snippet: ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Techniques: Immunohistochemistry, Generated, Microarray, Derivative Assay, Expressing